Anti-Inflammatory Peptide KPV Combined With Rapamycin Treats Vascular Calcification in Mice

Self-assembled KPV-RAPA carrier-free nanoparticles significantly inhibited vascular calcification in vitro and in vivo by simultaneously suppressing inflammation and activating autophagy, outperforming individual treatments.

Co-assembly of KPV peptide and rapamycin into carrier-free nanoparticles. Characterized stability and safety. Tested in both in vitro calcification models and in vivo mouse models of vascular calcification. Assessed inflammatory markers and autophagy activation.

Vascular calcification affects millions and has no approved drug therapy. By targeting two key disease mechanisms — inflammation and impaired autophagy — in a simple, safe nanoformulation, this peptide-drug combination addresses a critical unmet need in cardiovascular medicine.

Carrier-free nanomedicines solve major problems in drug delivery — they avoid the low drug loading, complex manufacturing, and safety risks of traditional nanocarriers. Using a bioactive peptide (KPV) as both a drug and a structural component of the nanoparticle is an elegant approach that could be applied to many other disease-drug combinations.

Preclinical study in mouse models that may not fully replicate human vascular calcification. Long-term safety unknown. Clinical translation requires extensive testing. Vascular calcification in humans involves complex pathways beyond inflammation and autophagy.